This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Top Analyst Reports for Apple, P&G, Deere & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), Procter & Gamble (PG), and Deere (DE).
Stock Market News for Feb 17, 2021
by Zacks Equity Research
The Dow booked a second straight record high on Tuesday with progress in Biden¿¿¿s $1.9 trillion coronavirus relief package and data showing COVID-19 cases dropping.
Gilead (GILD) & Galapagos Discontinue Development of IPF Drug
by Zacks Equity Research
Gilead (GILD) and partner Galapagos announce their decision to discontinue development of ziritaxestat in patients with idiopathic pulmonary fibrosis.
TEVA Stock Declines Despite Q4 Earnings and Sales Beat
by Zacks Equity Research
TEVA beats on fourth-quarter earnings and sales. It issues its financial guidance for 2021. Stock down.
The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Biogen, Gilead Sciences, Regeneron Pharma, Bristol-Myers Squibb and Incyte
Biotech Stock Roundup: Q4 Results of BMY, REGN, BIIB & Other Regulatory Updates
by Zacks Equity Research
Earnings of leading biotechs like Biogen (BIIB), Gilead (GILD) and Regeneron (REGN) dominate last week's headlines in the biotech sector.
Glaxo's (GSK) Rukobia Gets EU Nod for Multidrug-Resistant HIV
by Zacks Equity Research
The approval of Glaxo's (GSK) Rukobia is based on data from the pivotal phase III BRIGHTE study. Rukobia was approved in the United States in July last year.
Bristol Myers (BMY) Gets FDA Approval for CAR T-Cell Therapy
by Zacks Equity Research
Bristol Myers (BMY) obtains FDA approval of CAR T cell therapy, Breyanzi, for the treatment of lymphoma.
TEVA Gears Up to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.
How Will Biotech ETFs React to Q4 Earnings?
by Sweta Jaiswal, FRM
Let's take a look at some ETFs with exposure to major players in the U.S. biotech industry post their fourth-quarter earnings releases amid the coronavirus crisis.
Roche (RHHBY) 2020 Earnings Down Due to Biosimilars, COVID-19
by Zacks Equity Research
Roche's (RHHBY) performance in 2020 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.
Gilead (GILD) Tops Q4 Earnings & Sales on Strong Veklury Demand
by Zacks Equity Research
Gilead (GILD) reports better-than-expected results for the fourth quarter owing to increased Veklury sales as the coronavirus pandemic continues.
The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Ford, Pinterest, Peloton Interactive, Gilead Sciences and T-Mobile US
Massive Q4 Earnings Beats: Ford, Pinterest, Peloton & More
by Mark Vickery
There are so many companies hitting the tape with earnings reports in the after-hours, we only have time to touch on a few of them.
Gilead Sciences (GILD) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 1.86% and 4.36%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Ligand (LGND) Q4 Earnings & Sales Top, 2021 Guidance Raised
by Zacks Equity Research
Ligand (LGND) reports better-than-expected fourth-quarter 2020 numbers. The company raises outlook for 2021.
Tiziana (TLSA) Posts Positive Data on Nasal COVID-19 Antibody
by Zacks Equity Research
Tiziana (TLSA) reports positive data from a study investigating its anti-CD3 human monoclonal antibody, foralumab (nasally administered) for treating COVID-19 patients in Brazil. Shares up.
Will Eylea, Dupixent Drive Regeneron's (REGN) Q4 Earnings?
by Zacks Equity Research
Investors are likely to focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports fourth-quarter 2020 results.
SAP SE (SAP) Q4 Earnings and Revenues Decline Y/Y, Stock Down
by Zacks Equity Research
SAP SE (SAP) fourth-quarter results reflect lingering coronavirus crisis led business impacts on Concur solutions. However, gain from high demand for digital supply chain, Qualtrics and cloud platform solutions supported the top line.
Will Strong Veklury Sales Aid Gilead's (GILD) Q4 Earnings?
by Zacks Equity Research
Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports fourth-quarter 2020 results.
Eli Lilly (LLY) Q4 Earnings Top, COVID-19 Antibody Boosts Sales
by Zacks Equity Research
Lilly (LLY) beats fourth-quarter estimates for both earnings and sales. Stock up in pre-market trading.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $64.68, marking a -1.22% move from the previous day.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
5 Big Pharma/Biotech Stocks Set to Trump Q4 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks including Sanofi (SNY) and Merck (MRK) that are poised to beat fourth-quarter earnings estimates.
What's in the Cards for Amgen (AMGN) This Earnings Season?
by Zacks Equity Research
Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the fourth quarter is what remains to be seen when the company reports results.